Torbjörn Egelrud

Cormorant Pharmaceuticals AB provides biopharmaceutical products.The company was founded by Maarten de Chateau and Urban Paulsson in 2010 and is headquartered in Solna, Sweden.

Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Recipharm Holdings Ltd. operates from a multipurpose manufacturing facility, The company was founded on August 10, 2012 and is headquartered in Ashton-Under-Lyne, the United Kingdom.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

Provell Pharmaceuticals LLC is a healthcare company, which engages in marketing and distribution of pharmaceutical products. It offers products of Merck KGaA including Euthyrox. The company was founded by Jim Small and Kurt Kalm in 2005 and is headquartered in Honey Brook, PA.

Part of Recipharm AB, Recipharm Verwaltungs GmbH is an investment holding German company. The company is based in Wasserburg am Inn, Germany. The CEOs of the company are Michael Isele, Thomas Bengt Eldered.

Recipharm Ltd. manufactures pharmaceutical products. It offers branded and generic products. The company was founded on August 10, 2012 and is headquartered in Ashton-under-Lyne, the United Kingdom.

Cobra Biologics Ltd. engages in development of DNA-based technologies, services and products. It is a international contract development and manufacturing organization (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The company was founded in 1992 and is headquartered in Keele, the United Kingdom.

Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest.

Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.

Zentricity Holding AB provides investment services. It offers venture capital to startup companies. The company is headquartered in Stockholm, Sweden.

Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden.

Zentricity International AB provides investment services. The private company is based in Stockholm, Sweden.

Chromafora AB offers water purification and technology for selective heavy metal separation to a global market. It provides chemical reducing technology. Its services include selective metal extraction to handle waste streams containing dissolved heavy metals and chemical synthesis. The company was founded by Martin Kullberg, Karl Gaston Lavén, and Henrik Joachim Rundgren in 2010 and is headquartered in Solna, Sweden.

Part of Viatris, Inc., Recip AB is a company that manufactures pharmaceutical products. Recip AB is based in Arsta, Sweden. Recip was acquired by Meda AB, part of Viatris, Inc. from August 24, 2016 on December 31, 2007 for $475.65 million.

Part of Recipharm AB, Aesica Holdco Ltd. operates as a holding British company. The company is based in Hemel Hempstead, UK.

Flerie Participation AB is an investment holding Swedish company. The company is based in Stockholm, Sweden.

Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021.

Nylof Holding AB provides security brokerage services. The private company is based in Stockholm, Sweden.

AddBIO AB provides bone implant technology solutions. It offers Zolidd, a bioactive nanolayer with a bone strengthening drug. The firm's Zolidd is used in the areas of dental and trauma implants. It also offers Zolidiser, a machine to add bone-strengthening drugs to implants. The company was founded by Per Aspenberg and Trine Vikinge in 2008 and is headquartered in Linköping, Sweden.

Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022.

Aesica Formulation Development Ltd. develops pharmaceutical products. It offers sterile and nutraceutical product development and drug delivery services. The company was founded on December 22, 2005 and is headquartered in Northumberland, the United Kingdom.

Atrogi AB engages in research and development & sells type 2 diabetes (T2D) with minimal side effects. The company was founded by Tore Bengtsson and Andreas Bhagwani in 2013 and is headquartered in Solna, Sweden.

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.

Bohus BioTech AB is a Swedish company that manufactures and develops hyaluronic acid products. The company is based in Stromstad, Sweden and has subsidiaries in Sweden. The company was founded in 1992 by Daniel C. Ogbonnaya.